The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| SERES THERAPEUTICS INC | COM | 81750R102 | 128,604 | 12,682,876 | SH | DFND | 2 | 0 | 12,682,876 | 0 | |
| EDITAS MEDICINE INC | COM | 28106W103 | 51,455 | 1,674,435 | SH | DFND | 2 | 0 | 1,674,435 | 0 | |
| SYROS PHARMACEUTICALS INC | COM | 87184Q107 | 31,179 | 3,204,437 | SH | DFND | 2 | 0 | 3,204,437 | 0 | |
| QUANTERIX CORP | COM | 74766Q101 | 43,595 | 2,030,495 | SH | DFND | 0 | 2,030,495 | 0 | ||
| DENALI THERAPEUTICS INC | COM | 24823R105 | 139,489 | 8,918,749 | SH | DFND | 1 | 0 | 8,918,749 | 0 | |